samedan logo
home > news > detailed info

Clinical trial platform provider encapsia welcomes new COO


Horsham, United Kingdom, 5th January 2023: Clinical trial management solutions provider, encapsia, has announced the appointment of Francis Destin as its new Chief Operating Officer. Francis brings more than 20 years of expertise to the role, specialising in the management of data-related projects in clinical trials and statistical analysis software. His adoption of a future-facing approach to clinical research supports encapsia’s vision of transforming clinical trials for the benefit of the biotech, pharma and biopharma industries.

This approach aligns with encapsia's goal of developing user-friendly, adaptable solutions that have a long-term impact on decentralised clinical trials (DCTs) and data analysis. In turn, life science companies will benefit from the enhanced speed to market and cost-savings. Prioritising data insights to evaluate and select the best-performing techniques mirrors encapsia’s commitment to open access integration with expert systems such as randomisation and trial supply management systems (RTMS). Francis defines data as equalling shared knowledge and information, linking the company commitment to producing real-time data surfaced through user-friendly visualisations.

Commenting on the move, Francis said: “My journey with encapsia begins at a time of technological change, and I am looking forward to building on its many strengths in clinical data optimisation. The customer centric ethos fortifies my own approach, which is to create a holistic data management platform with user needs at the core. It’s all about looking to the future to see how we can improve our business mindset for the benefits of our customers and the wider industry.”

He continues: “There are a lot of companies competing within the technology landscape, and encapsia is uniquely positioned to drive the development of a more accessible, user-experience focused system. Whether the study is decentralised or not, EDC or eSource remains the central technology asset for data entry in a clinical trial. We’ve completely integrated this into our encapsia platform: a cloud application specifically designed for clinical studies that adapts to the needs of today, and ready for tomorrow. Real-world data (RWD) collection is at the heart of what encapsia does, and I look forward to driving our rapid growth.”

Encapsia’s Chief Technology Officer, Dr. Timothy Corbett-Clark, welcomes the move: “Encapsia is excited to have Francis on board and we are looking forward to drawing on his wealth of knowledge within the life science industry. We are eager to see what the future holds for the company and the leading figures driving it.”

Francis is spearheading the 5-year roadmap for encapsia, shifting the focus from solely electronic data capture (EDC) towards wearables and medical devices, and building on its partnerships with providers of transformative technologies. Encapsia will drive innovation in response to customer needs with the ultimate aim of creating a new platform that supports decentralised, hybrid and traditional clinical trials and encompasses feedback from sponsors and investigators. Its long-term strategic focus is to build an open access, customer centric solution that is dedicated to end users, keeps up with the pace of change in IoT devices and supports new demands as they arise. The open platform will not just be for developers but for everyone involved in the clinical trial process without requiring programming knowledge. This will formulate the new clinical trial design and ensure that encapsia and its customers are ready for the future.

Encapsia works to offer services and information to patients, but also technical support to investigators. For the patient, its technological roadmap considers better management and a thorough follow-up by analysing how they assess their health status and their trial experience. This enables the investigator to follow patients’ data allowing for more informed treatment decision-making. And for the promoter, improving adherence to treatments for a better understanding of patients' experience through the production and analysis of real-life data. This technological maturity will be accompanied by the delivery of specific support services around technical skills (software development, AI, cloud computing, etc.) and consider the different economic contexts.

Prior to joining encapsia, Francis worked as a Business and Innovation Director at Efor-CVO-Soladis, acquiring pertinent experience in project management and overseeing company strategy, to accelerate the development of Efor-CVO-Soladis’ cutting-edge technology. Its application in his new role at encapsia will create new business impact. Please visit Homepage | Encapsia for more information and insights.
phone +44 (0) 1403 755050
Print this page
Send to a friend
News and Press Releases

Stevanato Group collaborates with Recipharm to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with leading Contract Development and Manufacturing Organisation (CDMO), Recipharm. Under the agreement, Stevanato Group will lend its 70+ years of manufacturing experience to support the development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers. As part of this collaboration, Stevanato Group will provide and manufacture its glass pre-fillable syringe Alba® assembled with the Integrated Spray Module (ISM™) of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler (PFSI™).
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement